Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Alto Crescimento
A receita da empresa tem crescido de forma consistente nos últimos 3 anos, com média de 19.28% ano a ano.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 3.50M.
Avaliação Justa
O PE mais recente da empresa é -5.76, em uma faixa percentil média de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 14.22M ações, uma redução de 0.47% em relação ao trimestre anterior.
Mantido por The Vanguard
O Super Investidor The Vanguard possui 860.66K ações desta empresa.